Loading
SP
Satsuma Pharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Shin Nippon Biomedical Laboratories, Ltd., was filed 08 Jun 2023.
Satsuma Pharmaceuticals, Inc.: what insiders have been doing
Satsuma Pharmaceuticals, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). No insider at Satsuma Pharmaceuticals, Inc. has published a filing in the past twelve months. The most recent one dates from 12 June 2023.
Looking back to 2019, when coverage begins, insiders filed 30 purchases and 21 sales.
In the same sector, recent insider purchases at Xenon Pharmaceuticals Inc. and Vivos Inc also feature in our signals. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
88
Thresholds
n/a
Buy Volume
€79M
30 ops. · all time
Sell Volume
€3M
21 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
Income statement
Net income-US$60.3M
Last declaration on 12 June 2023
Declarations88 total
5,914,252 sharesCommon StockSEC:0001104659-23-070513:0
8,423,732 shares@ US$0.9127.5% of flowCommon StockSEC:0000899243-23-014866:1
Canonical exit: 6 Sept 2023 (T+90)
22,053,581 shares@ US$0.91100.0% of flowCommon StockSEC:0000899243-23-014866:0
Canonical exit: 4 Sept 2023 (T+90)
5,914,252 shares@ US$0.91100.0% of flowCommon Stock, $0.0001 par valueSEC:0000899243-23-014898:0
305,911 shares@ US$0.91100.0% of flowCommon Stock, $0.0001 par valueSEC:0000899243-23-014879:0
13,877 shares@ US$0.91100.0% of flowCommon Stock, $0.0001 par valueSEC:0000899243-23-014901:0
▲
Same trade as the filing by Shin Nippon Biomedical Laboratories, Ltd., counted once
20M USD31SEC
22,053,581 shares@ US$0.91100.0% of flowCommon Stock, $0.0001 par valueSEC:0000899243-23-014896:0
Canonical exit: 4 Sept 2023 (T+90)
150,000 shares@ US$0.71162.7% of flowCommon StockSEC:0001567619-22-020800:0
Canonical exit: 19 Feb 2023 (T+90)
531,000 shares@ US$0.63417.5% of flowCommon StockSEC:0001567619-22-020458:1
Canonical exit: 13 Feb 2023 (T+90)
300,694 shares@ US$0.62844.2% of flowCommon StockSEC:0001567619-22-020458:2
Canonical exit: 13 Feb 2023 (T+90)
5,608,306 shares@ US$0.689897.3% of flowCommon StockSEC:0001567619-22-020458:0
Canonical exit: 12 Feb 2023 (T+90)
3,250,000 shares@ US$0.70658.2% of flowCommon Stock, par value $0.0001 per shareSEC:0001493152-22-032622:0
2,922 shares@ US$5.420.4% of flowCommon Stock, par value $0.0001 per shareSEC:0000905718-21-001545:0
Canonical exit: 22 Feb 2022 (T+90)
9,979 shares@ US$5.491.1% of flowCommon Stock, par value $0.0001 per shareSEC:0000905718-21-001523:1
Canonical exit: 20 Feb 2022 (T+90)
3,225 shares@ US$5.440.4% of flowCommon Stock, par value $0.0001 per shareSEC:0000905718-21-001523:0
Canonical exit: 17 Feb 2022 (T+90)
7,941 shares@ US$6.050.9% of flowCommon Stock, par value $0.0001 per shareSEC:0000905718-21-001471:1
Canonical exit: 9 Feb 2022 (T+90)
9,622 shares@ US$5.851.3% of flowCommon Stock, par value $0.0001 per shareSEC:0000905718-21-001471:0
Canonical exit: 8 Feb 2022 (T+90)
560 shares@ US$5.990.1% of flowCommon Stock, par value $0.0001 per shareSEC:0000905718-21-001460:0
Canonical exit: 6 Feb 2022 (T+90)
7,800 shares@ US$5.950.9% of flowCommon Stock, par value $0.0001 per shareSEC:0000905718-21-001450:1
Canonical exit: 3 Feb 2022 (T+90)
1,400 shares@ US$5.880.2% of flowCommon Stock, par value $0.0001 per shareSEC:0000905718-21-001450:0
Canonical exit: 2 Feb 2022 (T+90)
8,880 shares@ US$5.641.1% of flowCommon Stock, par value $0.0001 per shareSEC:0000905718-21-001430:0
Canonical exit: 31 Jan 2022 (T+90)
44,651 shares@ US$5.715.7% of flowCommon Stock, par value $0.0001 per shareSEC:0000905718-21-001420:0
Canonical exit: 27 Jan 2022 (T+90)
15,082 shares@ US$5.551.6% of flowCommon Stock, par value $0.0001 per shareSEC:0000905718-21-001408:1
Canonical exit: 26 Jan 2022 (T+90)
39,581 shares@ US$5.454.9% of flowCommon Stock, par value $0.0001 per shareSEC:0000905718-21-001408:0
Canonical exit: 25 Jan 2022 (T+90)
27,629 shares@ US$5.512.9% of flowCommon Stock, par value $0.0001 per shareSEC:0000905718-21-001391:1
Canonical exit: 20 Jan 2022 (T+90)
25 of 88 declarations
About Satsuma Pharmaceuticals, Inc.
Satsuma Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company that traded on the NASDAQ under the ticker STSA. The company was founded in 2016 and built its business around migraine treatment, with its historical headquarters in South San Francisco, California, United States. From an equity-research perspective, Satsuma is best understood as a development-stage specialty pharma company with a narrow asset base and a high dependence on regulatory milestones, clinical execution, and eventual commercialization or strategic outcomes. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1692830/000156459021015557/stsa-10k_20201231.htm?utm_source=openai))
The company’s lead program was STS101, a proprietary nasal powder formulation of dihydroergotamine mesylate (DHE) for the acute treatment of migraine. Satsuma developed STS101 as a drug-device combination product, using a prefilled, single-use nasal delivery device designed to make administration faster and more convenient. The strategic logic was to differentiate an established active ingredient through formulation and delivery innovation, rather than by discovering a new molecular entity. That positioning placed Satsuma in a specialized corner of the migraine market, where treatment options include oral medications, nasal sprays, injectables, and newer biologic therapies. ([nasdaq.com](https://www.nasdaq.com/press-release/satsuma-pharmaceuticals-appoints-rob-janosky-as-chief-commercial-officer-2020-03-05?utm_source=openai))
Read moreShow less
In competitive terms, Satsuma operated in a crowded therapeutic category where efficacy, speed of onset, convenience, tolerability, and physician familiarity all matter. Its value proposition was centered on a compact, easy-to-use, non-injectable DHE option that could be self-administered in seconds. For investors, this meant the business case depended not on breadth of pipeline, but on whether STS101 could demonstrate a compelling clinical and commercial profile against established migraine therapies and other emerging options. ([nasdaq.com](https://www.nasdaq.com/press-release/satsuma-pharmaceuticals-appoints-rob-janosky-as-chief-commercial-officer-2020-03-05?utm_source=openai))
A major recent milestone was the FDA’s acceptance in May 2023 of Satsuma’s 505(b)(2) NDA for STS101, which represented an important regulatory step forward for the company. Public disclosures also showed that Satsuma had added commercial leadership earlier, highlighting preparations for a potential launch path. In addition, 2023 disclosures indicated that Satsuma was being acquired by SNBL, an important corporate development that materially changed the investment context around STSA and should be considered when reviewing insider activity and Form 4 filings. ([nasdaq.com](https://www.nasdaq.com/press-release/satsuma-pharmaceuticals-announces-fda-acceptance-of-505b2-nda-for-sts101-a-novel-and?utm_source=openai))
For French-speaking investors in Europe, Satsuma should be viewed as a niche U.S. NASDAQ biotech story in the United States, with a focused migraine franchise and a binary-risk profile typical of small-cap pharma development names. The investment thesis historically rested on the ability to turn a differentiated delivery format into regulatory approval and, ultimately, commercial value creation. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1692830/000156459021015557/stsa-10k_20201231.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
